Determination of the additional clinical value of contrast enhanced ultrasound imaging for the diagnosis of prostate cancer
Completed
- Conditions
- prostate cancerprostate carcinoma10038364
- Registration Number
- NL-OMON29721
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 250
Inclusion Criteria
Biopsy proven prostate carcinoma, treatment by (laparoscopic) radical prostatectomy
Exclusion Criteria
severe cardiac problems, severe hypertension
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Parameters of contrast enhanced ultrasound will be correlated and compared to<br /><br>the histology of the resected prostate. </p><br>
- Secondary Outcome Measures
Name Time Method <p>Adverse events of the used contrast agent</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie contrast enhanced ultrasound's role in prostate cancer detection?
How does contrast enhanced ultrasound compare to multiparametric MRI in diagnosing prostate carcinoma?
Which biomarkers correlate with enhanced ultrasound contrast uptake in prostate cancer patients?
What adverse events are associated with contrast enhanced ultrasound in prostate imaging?
Are there combination imaging strategies that improve contrast enhanced ultrasound for prostate cancer diagnosis?